TScan Therapeutics (NASDAQ:TCRX) Earns “Outperform” Rating from Wedbush

Wedbush reiterated their outperform rating on shares of TScan Therapeutics (NASDAQ:TCRX) in a research note published on Wednesday morning, RTT News reports. Wedbush currently has a $10.00 price objective on the stock. Wedbush also issued estimates for TScan Therapeutics’ Q1 2024 earnings at ($0.27) EPS, Q2 2024 earnings at ($0.23) EPS, Q3 2024 earnings at ($0.24) EPS, Q4 2024 earnings at ($0.25) EPS, FY2024 earnings at ($0.98) EPS, Q1 2025 earnings at ($0.26) EPS, Q2 2025 earnings at ($0.27) EPS, Q3 2025 earnings at ($0.28) EPS, Q4 2025 earnings at ($0.27) EPS, FY2025 earnings at ($1.08) EPS, FY2026 earnings at ($1.13) EPS and FY2027 earnings at ($0.91) EPS.

Separately, HC Wainwright restated a buy rating and issued a $15.00 price target on shares of TScan Therapeutics in a research note on Thursday, March 7th.

TScan Therapeutics Stock Down 1.4 %

Shares of NASDAQ TCRX opened at $6.82 on Wednesday. The stock has a market cap of $326.54 million, a P/E ratio of -3.61 and a beta of 0.90. The company has a current ratio of 6.51, a quick ratio of 6.51 and a debt-to-equity ratio of 0.18. TScan Therapeutics has a 12-month low of $1.62 and a 12-month high of $9.00. The business’s fifty day simple moving average is $7.06 and its 200-day simple moving average is $5.67.

TScan Therapeutics (NASDAQ:TCRX) last announced its quarterly earnings data on Wednesday, March 6th. The company reported ($0.21) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.29) by $0.08. The business had revenue of $7.21 million for the quarter, compared to analysts’ expectations of $2.94 million. TScan Therapeutics had a negative return on equity of 60.65% and a negative net margin of 423.86%. As a group, equities analysts predict that TScan Therapeutics will post -1.04 EPS for the current fiscal year.

Institutional Trading of TScan Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of TCRX. BlackRock Inc. raised its stake in TScan Therapeutics by 1.4% in the first quarter. BlackRock Inc. now owns 1,519,188 shares of the company’s stock valued at $4,254,000 after buying an additional 20,650 shares in the last quarter. Renaissance Technologies LLC acquired a new stake in TScan Therapeutics in the first quarter valued at $37,000. Woodline Partners LP raised its stake in TScan Therapeutics by 37.1% in the first quarter. Woodline Partners LP now owns 136,930 shares of the company’s stock valued at $383,000 after buying an additional 37,030 shares in the last quarter. LPL Financial LLC purchased a new position in shares of TScan Therapeutics during the second quarter worth about $50,000. Finally, Jane Street Group LLC purchased a new position in shares of TScan Therapeutics during the second quarter worth about $32,000. 82.83% of the stock is currently owned by institutional investors and hedge funds.

About TScan Therapeutics

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.